Study finds ketamine safe for patients with EDs, mood disorders
Abstract
Patients with eating disorders often face a double burden: not only do they struggle with the physical and psychological toll of their illness, but many also experience mood disorders that resist standard treatment. Depression and bipolar disorder are common among this population, and when conventional therapies fail, the risks escalate —suicidal thoughts and behaviors become more likely, and mortality rates climb, report the authors of a new study published in the Journal of Eating Disorders .
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.